end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableOtherCurrent,AccountsPayableTradeCurrent,AccruedIncomeTaxesCurrent,AccruedLiabilitiesCurrent,AccruedProfessionalFeesCurrent,AccruedRentNoncurrent,AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,AdditionalPaidInCapital,AdditionalPaidInCapitalCommonStock,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts,AllocatedShareBasedCompensationExpense,Assets,AssetsCurrent,AssetsHeldInTrustCurrent,AssetsNoncurrent,CashAndCashEquivalentsAtCarryingValue,CashAndCashEquivalentsFairValueDisclosure,CashCashEquivalentsAndShortTermInvestments,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1,CommonStockCapitalSharesReservedForFutureIssuance,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,ContractWithCustomerLiabilityRevenueRecognized,CostOfRevenue,CurrentFederalStateAndLocalTaxExpenseBenefit,CurrentForeignTaxExpenseBenefit,CurrentIncomeTaxExpenseBenefit,CurrentStateAndLocalTaxExpenseBenefit,DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction,DeferredCosts,DeferredOfferingCosts,DeferredTaxAssetsGoodwillAndIntangibleAssets,DeferredTaxAssetsGross,DeferredTaxAssetsNet,DeferredTaxAssetsOperatingLossCarryforwardsDomestic,DeferredTaxAssetsOther,DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals,DeferredTaxAssetsValuationAllowance,DefinedContributionPlanEmployerMatchingContributionPercentOfMatch,DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent,Depreciation,EarningsPerShareBasicAndDiluted,EffectiveIncomeTaxRateContinuingOperations,EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate,EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance,EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate,EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential,EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther,EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost,EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent,EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes,EmployeeRelatedLiabilitiesCurrent,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions,GeneralAndAdministrativeExpense,GrossProfit,IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic,IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign,IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments,IncomeTaxExpenseBenefit,IncomeTaxesPaid,IncreaseDecreaseInAccountsPayableTrade,IncreaseDecreaseInAccountsReceivable,IncreaseDecreaseInOtherAccountsPayable,IncreaseDecreaseInOtherNoncurrentLiabilities,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,IncreaseDecreaseInReceivables,InterestIncomeExpenseNonoperatingNet,LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,LiabilitiesNoncurrent,LossContingencyAccrualAtCarryingValue,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInInvestingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,OperatingIncomeLoss,OperatingLeaseExpense,OperatingLeasesFutureMinimumPaymentsDue,OperatingLeasesFutureMinimumPaymentsDueCurrent,OperatingLeasesFutureMinimumPaymentsDueInFourYears,OperatingLeasesFutureMinimumPaymentsDueInThreeYears,OperatingLeasesFutureMinimumPaymentsDueInTwoYears,OtherAssets,OtherAssetsNoncurrent,PaymentOfFinancingAndStockIssuanceCosts,PaymentsForProceedsFromLongtermInvestments,PaymentsForProceedsFromShortTermInvestments,PaymentsOfStockIssuanceCosts,PaymentsToAcquirePropertyPlantAndEquipment,PreferredStockSharesOutstanding,PrepaidExpenseAndOtherAssetsCurrent,ProceedsFromInterestReceived,ProceedsFromIssuanceInitialPublicOffering,ProceedsFromIssuanceOfCommonStock,ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock,ProceedsFromStockOptionsExercised,ProfitLoss,PropertyPlantAndEquipmentGross,PropertyPlantAndEquipmentNet,ReceivablesNetCurrent,RedeemableNoncontrollingInterestEquityPreferredCarryingAmount,ResearchAndDevelopmentExpense,RestrictedCash,RetainedEarningsAccumulatedDeficit,Revenues,SeveranceCosts1,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum,ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares,SharesIssuedPricePerShare,StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants,StockholdersEquity,StockholdersEquityNoteStockSplitConversionRatio1,StockIssuedDuringPeriodSharesStockOptionsExercised,StockIssuedDuringPeriodValueConversionOfConvertibleSecurities,StockIssuedDuringPeriodValueNewIssues,StockIssuedDuringPeriodValueStockOptionsExercised,TemporaryEquityLiquidationPreference,TemporaryEquitySharesAuthorized,TemporaryEquitySharesIssued,UnrecognizedTaxBenefits,UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions,UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions,UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued,ValuationAllowanceDeferredTaxAssetChangeInAmount,WeightedAverageBasicSharesOutstandingProForma,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,AccruedEmployeeBenefitsCurrent,AccruedProfessionalFeesCurrentAndNoncurrent,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,CommonStockOtherSharesOutstanding,CommonUnitIssued,ConversionOfStockSharesIssued1,CostsAndExpenses,DebtInstrumentInterestRateEffectivePercentage,DeferredOtherTaxExpenseBenefit,DeferredTaxAssetsInProcessResearchAndDevelopment,DeferredTaxAssetsTaxCreditCarryforwards,DeferredTaxAssetsTaxCreditCarryforwardsOther,DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities,DividendsCommonStock,EffectiveIncomeTaxRateReconciliationOtherAdjustments,EffectiveIncomeTaxRateReconciliationTaxContingenciesOther,EffectiveIncomeTaxRateReconciliationTaxCredits,EffectiveIncomeTaxRateReconciliationTaxSettlementsOther,EmployeeBenefitsAndShareBasedCompensation,LesseeOperatingLeaseLiabilityPaymentsDueYearFour,LesseeOperatingLeaseLiabilityPaymentsDueYearThree,NetIncomeLossAttributableToNonredeemableNoncontrollingInterest,OtherGeneralAndAdministrativeExpense,OtherResearchAndDevelopmentExpense,OtherTaxExpenseBenefit,PaymentsOfDebtIssuanceCosts,PaymentsToAcquireInProcessResearchAndDevelopment,ProceedsFromDebtNetOfIssuanceCosts,ProceedsFromIssuanceOfWarrants,PropertyPlantAndEquipmentOtherAccumulatedDepreciation,ResearchAndDevelopmentInProcess,RestrictedCashAndCashEquivalents,RestrictedCashEquivalents,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased,ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate,SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares,SharesIssued,StockIssuedDuringPeriodSharesRestrictedStockAwardGross,StockIssuedDuringPeriodSharesStockSplits,StockIssuedDuringPeriodValueOther,StockIssuedDuringPeriodValueShareBasedCompensation,UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued,UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense,WeightedAverageNumberOfDilutedSharesOutstanding,WeightedAverageNumberOfSharesOutstandingBasic,WeightedAverageNumberOfSharesRestrictedStock
2020-03-31,2020-06-22,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,3104000.0,3362000.0,,,,548000.0,,2063000.0,2063000.0,293000.0,,,15162000.0,11450000.0,81000.0,3712000.0,10055000.0,,10100000.0,10338000.0,-6470000.0,,,0.01,20000000.0,5064722.0,5003380.0,51000.0,,1001000.0,,,70000.0,,1133000.0,2050000.0,,,,,,,,,,,53000.0,-1.32,,0.21,,,,,,,,,,1311000.0,0.0,,-6477000.0,,,121000.0,40000.0,49000.0,532000.0,-20000.0,249000.0,-115000.0,,-38000.0,,15162000.0,6466000.0,548000.0,,-261000.0,182000.0,-6391000.0,-6598000.0,-6439000.0,,,,,,,,274000.0,261000.0,-202000.0,,,20000.0,,313000.0,24000.0,,,,0.0,6598000.0,,1388000.0,1001000.0,53373000.0,5128000.0,81000.0,-47339000.0,1001000.0,,293000.0,,,,,,,,,,,,,,,,,,,,,,,-45225000.0,,,,,,,,,,,,13000.0,,,4999563.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2020-06-30,2020-08-12,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,2220000.0,3565000.0,,,,534000.0,,107879000.0,,401000.0,2835000.0,,60275000.0,58627000.0,83000.0,1648000.0,57355000.0,,,57675000.0,,,,0.01,20000000.0,12779284.0,12660841.0,128000.0,,1045000.0,,,86000.0,,,,,,,,,,,,,,,-0.74,,0.21,,,,,,,,,,1546000.0,0.0,,-6573000.0,,,139000.0,,,,,,,,40000.0,,60275000.0,5785000.0,534000.0,,,,,-6712000.0,-6613000.0,,,,,,,,283000.0,,,,,,0.0,353000.0,,,,,,,,1365000.0,836000.0,,5067000.0,83000.0,-54051000.0,1045000.0,,,,,,,,,,,,,,,,,,,,,,,,,53955000.0,,,53373000.0,52119000.0,,,,,,,,13000.0,,,9018637.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2020-09-30,2020-11-16,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,2353000.0,3646000.0,,,,462000.0,,108294000.0,,402000.0,,,53393000.0,51751000.0,84000.0,1642000.0,48749000.0,,,49069000.0,,,,0.01,20000000.0,12781909.0,12670160.0,127000.0,,658000.0,,,,,,,,,,,,,,,,,,-0.59,,,,,,,,,,,,1862000.0,0.0,,-7323000.0,,,115000.0,,,,,,,,-40000.0,,53393000.0,5999000.0,462000.0,,,,,-7438000.0,-7283000.0,,,,,,,,285000.0,,,,,,0.0,2329000.0,,,,,,,,1357000.0,589000.0,,5421000.0,84000.0,-61489000.0,658000.0,,,,,,,,,,,,,,,,,,,,,,,,,46932000.0,,,,,13000.0,,,,,,,13000.0,,,12664485.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2020-12-31,2021-03-24,10-K,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,3151000.0,3726000.0,780000.0,3151000.0,657000.0,553000.0,182.0,109157000.0,,1569000.0,,1569000.0,45828000.0,44240000.0,90000.0,1588000.0,42025000.0,35900000.0,,42370000.0,25562000.0,,1083410.0,0.01,200000000.0,12824463.0,12728446.0,128000.0,3700000.0,3708000.0,426000.0,426000.0,426000.0,,,,0.0,651000.0,16425000.0,,12752000.0,0.0,3022000.0,16425000.0,1.0,0.06,182000.0,-3.06,-0.0143,0.21,-0.2665,0.0,-0.0007,-0.0111,-0.0111,-0.0007,0.0464,1613000.0,1200000.0,7371000.0,0.0,-29698000.0,-29721000.0,-29721000.0,-29721000.0,425000.0,58000.0,451000.0,212000.0,1644000.0,254000.0,1029000.0,212000.0,56000.0,,45828000.0,6877000.0,553000.0,0.0,52922000.0,181000.0,-27541000.0,-30146000.0,-29777000.0,300000.0,1207000.0,362000.0,121000.0,362000.0,362000.0,305000.0,305000.0,,-226000.0,-226000.0,,45000.0,0.0,1444000.0,58000.0,,52641000.0,0.0,281000.0,-30146000.0,1613000.0,1283000.0,681000.0,,22406000.0,90000.0,-70887000.0,3708000.0,200000.0,1569000.0,3907.0,58651.0,101929.0,18662.0,0.0,0.8,0.0203,0.0047,5.33,280107.0,3906.0,30938.0,177299.0,6.07,5.1,5.1,5.11,8.77,3350011.0,695674.0,,,38398000.0,10000.0,54999.0,53373000.0,52241000.0,281000.0,,,,581000.0,153000.0,3000.0,,16400000.0,9860610.0,9860610.0,1613000.0,657000.0,,,,,300000.0,0.23,,,12752000.0,651000.0,3022000.0,,0.022,-0.0085,,-0.0052,1569000.0,,,30146000.0,1060000.0,509000.0,,,101000.0,,,330000.0,3700000.0,,90000.0,15.0,,695674.0,6.07,,,,1695276000.0,200000.0,,96017.0,,,1569000.0,600000.0,,,,
2021-03-31,2021-05-14,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,2690000.0,3004000.0,,,,505000.0,,133358000.0,,852000.0,,,59233000.0,57850000.0,117000.0,1383000.0,56030000.0,,,56363000.0,13993000.0,,,0.01,200000000.0,13240961.0,13072213.0,131000.0,,974000.0,,,137000.0,,,,,,,,,,,,,,164000.0,-0.74,,0.21,,,,,,,,,,2303000.0,0.0,,-9320000.0,,,248000.0,48000.0,-1012000.0,-512000.0,-509000.0,0.0,88000.0,,-92000.0,,59233000.0,5694000.0,505000.0,,23642000.0,0.0,-9649000.0,-9568000.0,-9228000.0,,,,,,,,264000.0,0.0,0.0,,1665000.0,0.0,0.0,1534000.0,3000.0,,,,30000.0,9568000.0,,1119000.0,169000.0,,6925000.0,117000.0,-80455000.0,974000.0,,852000.0,,,,,,,,,,,,,,,,,,,,,,23322000.0,53034000.0,,,,,30000.0,,,,695000.0,111000.0,3000.0,30000.0,,,12888340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-06-30,2021-08-12,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,2377000.0,2833000.0,,,,502000.0,,133925000.0,,567000.0,,,48472000.0,47010000.0,119000.0,1462000.0,44412000.0,,,44753000.0,,0.01,,0.01,200000000.0,13240961.0,13092925.0,131000.0,,761000.0,,,,,,,,,,,,,,,,,,-0.75,,,,,,,,,,,,2536000.0,0.0,,-10679000.0,,,162000.0,,,,,,,,-22000.0,,48472000.0,5210000.0,502000.0,,,,,-10841000.0,-10657000.0,,1026000.0,181000.0,121000.0,362000.0,362000.0,,270000.0,,,,,,0.0,1550000.0,,,,,,,,1192000.0,929000.0,,8121000.0,119000.0,-91296000.0,761000.0,,,,,,,,,,,,,,,,,,,,,,,,,42760000.0,,,,,,,,,911000.0,209000.0,7000.0,39000.0,,,14417423.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-09-30,2021-11-15,10-Q,"Ayala Pharmaceuticals, Inc.",AYLA,CIK0001797336,USD,2979000.0,2888000.0,,,,493000.0,,140341000.0,,545000.0,5851000.0,,45744000.0,44324000.0,120000.0,1420000.0,40840000.0,,,41184000.0,,0.01,,0.01,200000000.0,13685554.0,13549362.0,135000.0,,625000.0,,,,,,,,,,,,,,,,,,-0.68,,,,,,,,,,,,2198000.0,,,-9629000.0,,,167000.0,,,,,,,,-63000.0,362000.0,45744000.0,5867000.0,493000.0,,,,,-9796000.0,-9566000.0,,1026000.0,91000.0,121000.0,362000.0,,272000.0,,,,,,,,2991000.0,,,,,,,,1148000.0,373000.0,,7368000.0,120000.0,-101092000.0,625000.0,,,,,,,,,,,,,,,,,,,,,,,,,39384000.0,,,,,24000.0,,,,904000.0,,7000.0,46000.0,,,14483629.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
